



## **Emergent BioSolutions to Release Full Year 2008 Financial Results and Conduct a Conference Call on March 5, 2009**

February 5, 2009

ROCKVILLE, Md.--(BUSINESS WIRE)-- Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for full year 2008 on Thursday, March 5, 2009, after market close.

Company management will host a conference call at 5:00 pm Eastern on March 5, 2009 to discuss these financial results, recent business developments and the outlook for 2009. The conference call will be accessible by dialing **888/679-8037** or **617/213-4849** (international) and providing passcode **51068666**. A webcast of the conference call will be accessible from the Company's website at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com), under "Investors".

Emergent BioSolutions is offering call participants a pre-registration option that expedites access to the call and minimizes hold times. Pre-registrants will be issued a pin number to be used when dialing into the live call which will provide quick access to the conference call by bypassing the operator upon connection. Pre-registration, while not mandatory, can be accessed using the following website: <https://www.theconferencingservice.com/prereg/key.process?key=PJU79TK8J>.

A replay of the conference call will be accessible, approximately one hour following the conclusion of the call, by dialing 888/286-8010 or 617/801-6888 and using the passcode 53418383. The replay will be available through March 19. The webcast will be archived on the company's website, [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com), under "Investors".

### **About Emergent BioSolutions Inc.**

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of immune-related biologic products, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax<sup>®</sup> (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's development pipeline includes programs focused on anthrax, botulism, typhoid, tuberculosis, hepatitis B and chlamydia. Additional information may be found at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com).

Source: Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

#### **Investors Contact:**

Robert G. Burrows  
Vice President, Investor Relations  
**301-795-1877**

[BurrowsR@ebsi.com](mailto:BurrowsR@ebsi.com)

or

#### **Media Contact:**

Tracey Schmitt  
Director, Corporate Communications  
**301-795-1800**

[SchmittT@ebsi.com](mailto:SchmittT@ebsi.com)